ReviewHeart failure reviews2023
Advance of echocardiography in cardiac amyloidosis.
Review in Heart failure reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 24 citations in OpenAlex.
- Myocardial work in light-chain and transthyretin-related amyloidosis with preserved ejection fraction: a cardiovascular magnetic resonance study.Insights into imaging · 2026Article
- Evaluation of echocardiographic features and cardiac biomarkers in patients with AA amyloidosis: a retrospective comparative study with patients with al amyloidosis and hypertrophic cardiomyopathy.Rheumatology international · 2026Observational
- Complete Heart Block Unmasking Transthyretin Cardiac Amyloidosis: A Multimodality Imaging Case Report.Cureus · 2026Article
- Characteristics and clinical significance of myocardial work in cardiac light-chain amyloidosis: pressure-volume loop analysis based on cardiovascular magnetic resonance.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2026Article
- Echocardiographic Red Flags in Wild-Type Transthyretin Amyloidosis: Sex-Specific Gaps for Wall Thickness and Left Ventricular Mass.Life (Basel, Switzerland) · 2026Article
- E/e' ratio combined with left ventricular mass index predicts HFpEF rehospitalization risk in stage 3-4 chronic kidney disease patients: a retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- The value of speckle tracking echocardiography in early identification of subclinical cardiac involvement in patients with multiple myeloma: a pilot retrospective study.Frontiers in medicine · 2026Article
- The Arrhythmic Burden of Cardiac Amyloidosis: A Comprehensive Review.Heart views : the official journal of the Gulf Heart Association · 2026Review
- Advances in imaging-based diagnosis, prognosis, and response assessment in cardiac amyloidosis: a comprehensive multimodality review.Annals of nuclear medicine · 2025Review
- What Cardiologists Should Know About Amyloidosis.Journal of clinical medicine · 2025Review
- A Comparative Analysis of Cardiac Amyloidosis and Cardiac Sarcoidosis: A Single-Center Experience.Journal of clinical medicine · 2025Article
- Article
- Navigating Diagnostic Ambiguities in Cardiac Amyloidosis: Insights from a Case with Delayed Diagnosis of AL Amyloidosis.The American journal of case reports · 2025Article
- Advances and challenges in echocardiographic diagnosis and management of cardiac amyloidosis.The international journal of cardiovascular imaging · 2025Review
- Screening for Cardiac Amyloidosis When Conducting Carpal Tunnel Surgery.Journal of clinical medicine · 2025Article
- Article
- Echocardiographic Features of Wild-Type Transthyretin Cardiac Amyloidosis From J-Case: Multicenter Survey in Japan.JACC. Asia · 2025Article
- Transthyretin Amyloid Cardiomyopathy: Current Diagnostic Approach and Risk Stratification with Multimodality Imaging.Journal of clinical medicine · 2025Review
- Advancements in Cardiac Amyloidosis Treatment.Biomedicines · 2024Review
- Diagnosing AL and ATTR Amyloid Cardiomyopathy: A Multidisciplinary Approach.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac amyloidosis (CA) occurs when the insoluble fibrils formed by misfolded precursor proteins deposit in cardiac tissues. The early clinical manifestations of CA are not evident, but it is easy to progress to refractory heart failure with an inferior prognosis. Echocardiography is the most commonly adopted non-invasive modality of imaging to visualize cardiac structures and functions, and the preferred modality in the evaluation of patients with cardiac symptoms and suspected CA, which plays a vital role in the diagnosis, prognosis, and long-term management of CA. The present review summarizes the echocardiographic manifestations of CA, new echocardiographic techniques, and the application of multi-parametric echocardiographic models in CA diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.